![](/img/cover-not-exists.png)
A New Subcutaneous Immunoglobulin 20% Formulation (SCIG 20%) with Individualized Infusion Parameters Resulted in a Positive Safety and Tolerability Profile in Patients with PIDD in Europe and North America
Suez, Daniel, Krivan, Gregely, Jolles, Stephen R., Hussain, Iftikhar, Stein, Mark R., Gupta, Sudhir, Paris, Kenneth, van Hagen, Martin, Brodszki, Nicholas, McCoy, Barbara, Yel, LemanVolume:
139
Language:
english
Journal:
Journal of Allergy and Clinical Immunology
DOI:
10.1016/j.jaci.2016.12.700
Date:
February, 2017
File:
PDF, 127 KB
english, 2017